1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. Class A

Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. Class A

SSZSE:000766
15.07
CNY
+0.04
(+0.27%)
0.02EPS
867.15P/E
18.75BMarket Cap
Tonghua Golden-Horse Pharmaceutical Industry Co. Ltd. Class A
SZSE:000766
(Shenzhen Stock Exchange)

Recent

price

15.07

P/E

ratio

867.15

div

yld

0.57%

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
0.42
0.48
0.33
0.36
0.4
0.29
0.92
1.59
2.15
2.04
1.14
1.72
1.46
1.68
1.41
1.36
1.23
Revenue per Share
0.03
0.03
0.01
0.01
0.01
0.01
0.23
0.27
0.34
-2.11
-0.37
0.04
0.03
0.05
0.06
0.04
0.02
Basic EPS, GAAP
0.05
-0.04
-0.07
-0.13
-0.29
-0.28
-0.08
-0.1
0.1
0.01
0.06
0.13
0.17
0.1
0.12
0.05
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.01
0.02
0.02
0.03
0.03
0.04
0.13
0.11
0.09
0.09
0.09
0.09
0.09
Dividend per Share
1.33
1.35
1.38
1.37
1.47
3.92
4.27
4.53
4.83
2.72
2.35
2.39
2.42
2.4
2.33
2.39
2.4
Book Value per Share
0.97
0.99
1.03
0.95
1.06
0.39
1.78
2.06
2.27
2.3
1.94
1.99
2.03
2.01
1.94
1.98
1.99
Tangible Book Value per Share
401
375
386
409
517
686
928
955
973
968
972
882
1,005
879
941
857
968
Basic Weighted Avg Shares
170
181
128
148
208
198
850
1,521
2,095
1,977
1,112
1,515
1,471
1,473
1,323
1,170
1,186
Sales/Revenue/Turnover
8.17
2.12
-3.95
-10.95
2.59
-7.55
25.95
19.99
14.82
6.46
-15.69
8.11
8.77
9.73
11.42
10.36
9.77
Operating Margin (%)
18
17
17
16
15
16
54
61
67
68
68
69
72
75
67
62
- -
Depreciation Expense
12
11
4
4
5
7
213
258
331
-2,042
-359
35
30
44
56
34
22
Net Income, GAAP
- -
31.49
24.04
21.32
40.79
- -
14.47
14.28
19.55
- -
- -
43
41.82
21.2
16.56
19.92
26.85
Effective Tax Rate (%)
7.09
6.19
3.02
2.77
2.48
3.47
25.11
16.95
15.8
-103.27
-32.33
2.33
2.05
2.98
4.27
2.93
1.83
Profit Margin (%)
235
251
255
47
74
-940
771
846
884
782
765
-876
567
539
-947
682
700
Working Capital
- -
- -
- -
- -
200
145
206
156
322
983
1,818
188
1,568
1,560
3
1,589
1,585
LT Debt
596
607
620
615
659
2,246
4,161
4,419
4,709
2,666
2,305
2,339
2,369
2,318
2,255
2,310
2,317
Total Equity
- -
1.38
0.9
0.43
1.29
- -
5.64
5.25
6.21
- -
- -
0.86
0.73
1
1.4
0.86
0.53
Return on Invested Capital (%)
- -
1.87
0.63
0.98
1.04
- -
6.58
5.78
6.98
- -
- -
2.14
1.98
2.69
3.16
2.44
1.97
Return on Capital (%)
2.04
1.87
0.63
0.66
0.81
0.47
6.7
6.07
7.31
-55.91
-14.67
1.54
1.3
1.89
2.47
1.5
0.94
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
226
436
437
LT Borrowings
1,586
1,583
1,582
LT Finance Leases
3
3
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
966
966
966
Market Capitalization
26,569
18,711
18,750

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,195
1,473
1,440
Cash, Cash Equivalents & STI
273
497
489
Accounts Receivable, Net
483
544
541
Inventories
365
352
346
Total Current Liabilities
513
775
740
Payables & Accruals
- -
- -
- -
ST Debt
226
436
437
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.14%
0.06%
2.44%
Free Cash Flow
6.61%
11.05%
-63.91%
Net Income, GAAP
217.04%
-17.88%
-39.25%
Sales/Revenue/Turnover
40.93%
2.35%
-11.54%
Total Cash Common Dividend
32.43%
-8.58%
-4.31%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
296
354
319
354
1,323
2025
299
351
- -
278
1,170
2026
300
257
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
0.01
0.03
0.06
2025
0.01
0.01
- -
0.01
0.04
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
0.02
0.02
0.02
0.09
2025
0.02
0.02
- -
0.02
0.09
2026
0.02
0.02
- -
- -
- -
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Tonghua Golden-Horse Pharmaceutical Industry Co., Ltd. specializes in the research, development, production, and distribution of a diverse range of pharmaceutical goods within China and is expanding its international presence. The company’s comprehensive portfolio addresses key therapeutic areas including oncology, cardiovascular health, microbial infections, digestive disorders, musculoskeletal conditions, and gynecological and neurological systems. It provides an array of Traditional Chinese Medicines, modern chemical drugs, biopharmaceuticals, and innovative treatments, encompassing both prescription and over-the-counter options. These offerings are delivered in various forms, such as capsules, tablets, injections, and oral liquids. Founded in 1990, the enterprise is headquartered in Tonghua, China, and is actively pursuing the commercialization of an innovative Class I drug for Alzheimer’s disease, while also strategically investing in new research and development subsidiaries.